Lotus Pharmaceutical Co., Ltd.

TWSE:1795 Stock Report

Market Cap: NT$69.1b

Lotus Pharmaceutical Past Earnings Performance

Past criteria checks 4/6

Lotus Pharmaceutical has been growing earnings at an average annual rate of 39.5%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 14% per year. Lotus Pharmaceutical's return on equity is 21.4%, and it has net margins of 24.6%.

Key information

39.5%

Earnings growth rate

38.2%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate14.0%
Return on equity21.4%
Net Margin24.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Nov 14
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Recent updates

Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings

Dec 04
Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings

Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 16
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Nov 14
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Oct 23
Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Revenue & Expenses Breakdown

How Lotus Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TWSE:1795 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2417,5944,3334,094503
30 Jun 2416,9334,0143,972588
31 Mar 2416,6323,9483,812493
31 Dec 2316,9584,1063,760541
30 Sep 2316,7103,8733,569537
30 Jun 2317,5274,7073,452504
31 Mar 2315,9953,7693,370483
31 Dec 2214,6333,0213,138419
30 Sep 2214,2643,1052,925411
30 Jun 2211,9321,3742,792330
31 Mar 2212,4861,4012,679397
31 Dec 2112,6491,4032,738374
30 Sep 2112,9771,4702,774408
30 Jun 2112,8061,4002,736460
31 Mar 2112,0191,3442,642371
31 Dec 2010,7291,0272,472384
30 Sep 2010,8028482,379469
30 Jun 209,9337692,365431
31 Mar 209,3075192,520470
31 Dec 199,6116632,545465
30 Sep 198,1305962,455434
30 Jun 197,6934632,387375
31 Mar 197,2783592,266323
31 Dec 186,429992,232318
30 Sep 186,537382,232301
30 Jun 186,535192,198316
31 Mar 186,4771102,099313
31 Dec 176,424222,086289
30 Sep 176,072-1712,062415
30 Jun 175,897-2522,176414
31 Mar 175,913-2702,342411
31 Dec 165,903-1342,396416
30 Sep 165,896782,510316
30 Jun 165,9101262,487322
31 Mar 165,6531982,423314
31 Dec 155,5221042,481299
30 Sep 154,712-1022,405256
30 Jun 153,879-2042,137209
31 Mar 153,125-3121,845177
31 Dec 142,310-4421,458132
30 Sep 142,201-3071,169124
30 Jun 142,152-2691,10280
31 Mar 142,411-3301,19937
31 Dec 132,092-1431,00564

Quality Earnings: 1795 has high quality earnings.

Growing Profit Margin: 1795's current net profit margins (24.6%) are higher than last year (23.2%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 1795's earnings have grown significantly by 39.5% per year over the past 5 years.

Accelerating Growth: 1795's earnings growth over the past year (11.9%) is below its 5-year average (39.5% per year).

Earnings vs Industry: 1795 earnings growth over the past year (11.9%) did not outperform the Pharmaceuticals industry 11.9%.

Return on Equity

High ROE: 1795's Return on Equity (21.4%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 15:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lotus Pharmaceutical Co., Ltd. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCapital Securities Corporation
Jianzheng WuCapital Securities Corporation
Hsuan ChenKGI Securities Co. Ltd.